Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Versant Venture Capital VI, L.P. Insider Profile
4 Followers
Versant Venture Capital VI, L.P., Ten Percent Owner at Akero Therapeutics, holds 8.33M shares in Monte Rosa Therapeutics (Ticker: GLUE), holds 6.21M shares in Black Diamond Therapeutics (Ticker: BDTX), holds 3.51M shares in Tempest Therapeutics (Ticker: TPST). Most recently, Versant Venture Capital VI, L.P. Sold ― shares of Monte Rosa Therapeutics on Sep 13, 2024 for an estimated value of 3.40M.
Versant Venture Capital VI, L.P. Akero Therapeutics (AKRO)Ten Percent Owner
Akero Therapeutics (AKRO)
Ten Percent Owner
Ranked #84,954 out of 98,834 Corporate Insiders
Profitable Transactions
3 out of 11 Profitable Transactions
Average Return
-18.50%
Average return per transaction
Time Frame
Compare to
Insider Holdings
A breakdown of Versant Venture Capital VI, L.P.'s holdings
Insider Roles
Roles that Versant Venture Capital VI, L.P. holds in companies
Most Profitable Insider Trade
The most profitable trade made by Versant Venture Capital VI, L.P.
Versant Venture Capital VI, L.P.'s Trading History
Akero Therapeutics
Jan 21, 2020
Ten Percent Owner
Uninformative Sell
1.24M
$82.39M
Oyster Point Pharma
Jan 04, 2023
―
Uninformative Sell
―
$0.00
Black Diamond Therapeutics
Aug 30, 2024
Ten Percent Owner
Informative Sell
1.40M
$29.95M
Passage Bio
Mar 03, 2020
Ten Percent Owner
Uninformative Buy
―
$3.61M
Pandion Therapeutics
Jul 21, 2020
―
Uninformative Buy
―
$225.43M
Aligos Therapeutics
Oct 20, 2020
Ten Percent Owner
Uninformative Buy
―
$47.38M
Century Therapeutics
Aug 11, 2022
Ten Percent Owner
Uninformative Sell
7.17M
$20.20M
LENZ Therapeutics
Mar 25, 2024
Ten Percent Owner
Uninformative Buy
―
$95.84M
Monte Rosa Therapeutics
Sep 13, 2024
Ten Percent Owner
Informative Sell
3.40M
$49.31M
Tempest Therapeutics
Aug 12, 2024
Ten Percent Owner
Informative Sell
966.80K
$5.30M
Contineum Therapeutics, Inc. Class A
―
Ten Percent Owner
―
$9.64M
List of latest transactions for each holding click on a transaction to see Versant Venture Capital VI, L.P.'s performance on stock
You May Also Like
Versant Venture Capital VI, L.P. insider profile FAQ
What is the percentage of profitable transactions made by Versant Venture Capital VI, L.P.?
The percentage of profitable transactions made by Versant Venture Capital VI, L.P. is 27%.
What is the average return per transaction made by Versant Venture Capital VI, L.P.?
The average return per transaction made by Versant Venture Capital VI, L.P. is -18.50%.
What stocks does Versant Venture Capital VI, L.P. hold?
Versant Venture Capital VI, L.P. holds: AKRO, OYST, BDTX, PASG, PAND, ALGS, IPSC, LENZ, GLUE, TPST, CTNM stocks.
What was Versant Venture Capital VI, L.P.’s latest transaction?
Versant Venture Capital VI, L.P. latest transaction was an Informative Sell of $3.40M.
What was Versant Venture Capital VI, L.P.'s most profitable transaction?
Versant Venture Capital VI, L.P.’s most profitable transaction was an Informative Buy of AKRO stock on June 25, 2019. The return on the trade was 39.40%.
What is Versant Venture Capital VI, L.P.'s role in Akero Therapeutics?
Versant Venture Capital VI, L.P.'s role in Akero Therapeutics is Ten Percent Owner.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.